Q3 2025 EPS Estimates for Alkermes plc Increased by Zacks Research (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS - Free Report) - Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for shares of Alkermes in a research note issued on Wednesday, April 10th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.52 per share for the quarter, up from their previous estimate of $0.43. The consensus estimate for Alkermes' current full-year earnings is $2.23 per share.

Other analysts have also recently issued reports about the company. StockNews.com cut Alkermes from a "strong-buy" rating to a "buy" rating in a report on Friday, February 23rd. Jefferies Financial Group boosted their target price on Alkermes from $42.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday. UBS Group lowered Alkermes from a "neutral" rating to a "sell" rating and set a $25.00 target price for the company. in a research report on Tuesday, February 20th. Bank of America boosted their target price on Alkermes from $27.00 to $29.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 2nd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $39.00 price objective on shares of Alkermes in a research report on Monday, April 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.25.

Alkermes Trading Down 2.3 %

NASDAQ:ALKS traded down $0.57 on Friday, hitting $24.42. 1,895,023 shares of the stock were exchanged, compared to its average volume of 1,902,321. The stock has a market capitalization of $4.13 billion, a price-to-earnings ratio of 11.86 and a beta of 0.55. Alkermes has a 52 week low of $22.01 and a 52 week high of $33.71. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.50 and a current ratio of 2.86. The company's 50-day moving average price is $28.17 and its 200 day moving average price is $27.19.

Alkermes (NASDAQ:ALKS - Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.29). The firm had revenue of $377.50 million for the quarter, compared to the consensus estimate of $362.78 million. Alkermes had a return on equity of 16.10% and a net margin of 21.39%. The business's revenue for the quarter was up 23.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.02) earnings per share.

Alkermes announced that its Board of Directors has initiated a share repurchase program on Thursday, February 15th that authorizes the company to buyback $400.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 8.2% of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its stock is undervalued.

Insider Buying and Selling at Alkermes

In other Alkermes news, SVP Christian Todd Nichols sold 10,417 shares of the business's stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $28.10, for a total value of $292,717.70. Following the sale, the senior vice president now owns 65,911 shares in the company, valued at approximately $1,852,099.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.76% of the company's stock.

Institutional Investors Weigh In On Alkermes

Several institutional investors have recently bought and sold shares of ALKS. JPMorgan Chase & Co. bought a new stake in Alkermes in the 1st quarter valued at approximately $4,369,000. Raymond James & Associates raised its stake in shares of Alkermes by 132.4% during the 1st quarter. Raymond James & Associates now owns 32,763 shares of the company's stock worth $862,000 after purchasing an additional 18,667 shares in the last quarter. US Bancorp DE raised its stake in shares of Alkermes by 24.0% during the 1st quarter. US Bancorp DE now owns 10,571 shares of the company's stock worth $279,000 after purchasing an additional 2,044 shares in the last quarter. Bank of Montreal Can bought a new stake in shares of Alkermes during the 1st quarter worth approximately $203,000. Finally, Acadian Asset Management LLC raised its stake in shares of Alkermes by 660.7% during the 1st quarter. Acadian Asset Management LLC now owns 21,945 shares of the company's stock worth $576,000 after purchasing an additional 19,060 shares in the last quarter. Institutional investors own 95.21% of the company's stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.